

# Rates of Psychotropic Medication Use at Vermont Correctional Facilities

## Women at Dale and Southeast Correctional Facilities for the Entire Month of January by Age

	# Prisoners	% with Any	% with Anti-depressants*	% with Trazodone	% with Antipsychotics	% with Mood Stabilizers	% with Anti-anxiety
Total	112 ± 2	52% ± 2%	46% ± 2%	17% ± 1%	11% ± 1%	11% ± 1%	4% ± 0%
18-34	67 ± 2	42% ± 3%	36% ± 3%	10% ± 1%	8% ± 1%	6% ± 1%	3% ± 0.3%
35-49	35 ± 1	60% ± 3%	54% ± 3%	20% ± 1%	17% ± 1%	14% ± 1%	3% ± 0.1%
50+	10 ± 0.4	90% ± 5%	80% ± 5%	50% ± 4%	10% ± 0.4%	30% ± 2%	10% ± 0.4%

## Women at Dale Women's Facility for the Entire Month of January by Age

	# Prisoners	% with Any	% with Anti-depressants*	% with Trazodone	% with Antipsychotics	% with Mood Stabilizers	% with Anti-anxiety
Total	39 ± 1	56% ± 2%	51% ± 2%	26% ± 1%	15% ± 1%	13% ± 1%	5% ± 1%
18-34	26 ± 1	46% ± 3%	38% ± 3%	12% ± 1%	12% ± 1%	3.8% ± 0.1%	8% ± 1%
35-49	8 ± 0.4	62% ± 5%	62% ± 5%	50% ± 3%	25% ± 3%	12% ± 1%	0% ± 0%
50+	5 ± 0.2	100% ± 6%	100% ± 6%	60% ± 5%	20% ± 1%	60% ± 5%	0% ± 0%

## Women at Southeast State Correctional Facility for the Entire Month of January by Age

	# Prisoners	% with Any	% with Anti-depressants*	% with Trazodone	% with Antipsychotics	% with Mood Stabilizers	% with Anti-anxiety
Total	74 ± 1	48% ± 2%	42% ± 2%	12% ± 1%	8% ± 0.5%	9% ± 1%	2.7% ± 0.05%
18-34	41 ± 1	39% ± 3%	34% ± 2%	10% ± 1%	5% ± 1%	7% ± 1%	0% ± 0%
35-49	28 ± 1	57% ± 3%	50% ± 2%	11% ± 1%	14% ± 1%	14% ± 1%	4% ± 0.1%
50+	5 ± 0.3	80% ± 6%	60% ± 5%	40% ± 4%	0% ± 0%	0% ± 0%	20% ± 1%

\*Trazodone HCl was not included as an antidepressant medication and was included as a separate medication for this analysis.

Analysis based on the Department of Corrections (DOC) institutional data set and DOC pharmacy data set, and includes adults (aged 18 and over) who were institutionalized at the same facility during the entire month of January, CY2007. This analysis includes antidepressant, antipsychotic, mood stabilizer, and anti-anxiety medications. Antidepressants include drugs with an antidepressant therapeutic class (H2U,H2X,H7B), or a SSRIS, SNRIS, NDRIS, or SARIS therapeutic drug class (H2S,H7C,H7D,H7E). Trazodone HCl was not included in antidepressants and was included as a separate medication. Antipsychotics include drugs with typical or atypical antipsychotic therapeutic class (H2G,H7O,H7R,H7S,H7T,H7U,H7X). Mood stabilizers include drugs with an anti-mania or anticonvulsant therapeutic class (H2M,H4B). Anti-anxiety medication include drugs with an anti-anxiety drug therapeutic class (H2F).

Because the data sets used in this analysis do not share unique person identifiers, Probabilistic Population Estimation was used to determine the number of individuals in these institutions who received mood stabilizer, antipsychotic and/or antidepressant medications.